Masayoshi Son's SoftBank has 67% of its US stock portfolio parked in Intel, and the firm didn't buy a single additional share last quarter. The heavy concentration in one chipmaker leaves the portfolio vulnerable to Intel's share price swings and exposes SoftBank to strategic risk if the semiconductor market shifts.
A Portfolio That Rides on One Chipmaker
SoftBank's US equity holdings are overwhelmingly weighted toward Intel. The latest data shows Intel accounting for more than two-thirds of the company's US-listed stocks. That's a level of concentration that would be unusual for most institutional investors, and it means SoftBank's US performance is essentially a proxy for Intel's stock.
The firm didn't add to that position last quarter. No new Intel shares were purchased, leaving the stake unchanged in share count. But because the portfolio is so lopsided, any move in Intel's price directly shifts the weight of the bet.
No Fresh Purchases, Same Exposure
Without new buys, the weighting changes only with the stock's price. If Intel climbs, the concentration grows. If it falls, the weighting shrinks. SoftBank's managers didn't act to rebalance, so the portfolio's risk profile is whatever Intel's share price dictates.
That's a passive approach to a very active bet. The firm didn't trim or add, which suggests a wait-and-see posture. But with two-thirds of the book in one name, there's little room for drift.
The decision not to buy more Intel shares could mean SoftBank is comfortable with its exposure, or that it's waiting for a more favorable entry point. Either way, the firm's US portfolio remains a one-stock bet.
The Risks of a Single-Stock Bet
Concentrated portfolios are more volatile than diversified ones. A single stock's bad quarter can drag down the entire US portfolio. For SoftBank, that means Intel's earnings, guidance, and product cycles matter more than any other factor in its US holdings.
Strategic risk is also part of the picture. If Intel's business model faces disruption—from competitors or shifts in chip demand—SoftBank's US exposure takes the hit directly. There's no cushion from a broader mix of stocks.
The concentration also highlights a management challenge. With such a large stake, selling any meaningful portion would likely move the market. That makes it harder to adjust the position quickly if Intel's outlook deteriorates.
SoftBank's next quarterly filing will show whether the Intel position changes. Until then, the firm's US portfolio is a one-company story.
